Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | THRA | P10827 | 9/20 | 0.47 |
| ▸ | THRB | P10828 | 9/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282686 | 0.85 | THRB (0.48) | THRATHRB | |
| SCHEMBL282123 | 0.84 | THRA (0.38) | ADRA2AADRA2BADRA2CADRA1ATHRA | |
| SCHEMBL282702 | 0.83 | THRA (0.69) | ADRA2AADRA2BADRA2CADRA1ATHRA | |
| SCHEMBL282370 | 0.82 | THRB (0.47) | THRATHRB | |
| SCHEMBL13381700 | 0.80 | THRA (0.56) | ADRA2AADRA2BADRA2CADRA1ATHRA | |
| SCHEMBL3159430 | 0.80 | THRB (0.67) | THRATHRB | |
| SCHEMBL286825 | 0.80 | THRA (0.49) | THRATHRB | |
| SCHEMBL282558 | 0.80 | THRB (0.49) | THRATHRB | |
| SCHEMBL282421 | 0.80 | THRB (0.53) | THRATHRB | |
| SCHEMBL22071770 | 0.80 | THRA (0.55) | ADRA2AADRA2BADRA2CADRA1ATHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428516-A1 | Novel phosphorus-containing thyromimetics | Metabasis Therapeutics, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1891080-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1890768-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128056-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128055-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | PYGL, THRA, THOP1 | ADRA2A 3338/4885ADRA2B 3613/4885ADRA2C 2738/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | ADRA2A 3338/4885ADRA2B 3613/4885ADRA2C 2738/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | ADRA2A 3672/4885ADRA2B 3960/4885ADRA2C 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.